An improved and economically viable process is described to prepare N-(1-(3-(2-fluorophenyl) quinoxalin-2-yl) pyrrolidin-3-yl) derivatives. Initially tert-butyl 1-(3-chloroquinoxalin-2-yl) pyrrolidin-3-yl carbamate (2) was prepared by treating of 2, 3-dichloroquinoxaline (1) with tert-butyl pyrrolidin-3-ylcarbamate and sodium carbonate in t-butanol. Tert-butyl 1-(3-chloroquinoxalin-2-yl) pyrrolidin-3-yl carbamate (2) is reacted with Bis-(diphenylphosphino)-ferrocene dichloropalladium (II), complex PdCl2 (dppf). DCM (6% mol) and substituted phenyl boronic acid is refluxed overnight in presence toluene to form tert-butyl 1-(3-(2-fluorophenyl) quinoxalin-2-yl) pyrrolidin-3-ylcarbamate and its related substituted compounds (3a-c). Deprotection of (3a-c) by TFA at 0-5°C in dichloroethane in presence of microporous tosic acid (MP-TSOH) to give 1-(3-(2-fluorophenyl) quinoxalin-2-yl) pyrrolidin-3-amine and its related compounds (4a-c). Amidation of deprotected product (4a-c) by dissolved in dichloroethane with Polymer Supported Triethylamine (PL-TEA) and respective acid chloride to obtained 1-(3-(2-fluorophenyl) quinoxalin-2-yl) pyrrolidin-3-amine derivatives (5a-d). Antibacterial activities of these compounds were studied.
Select your language of interest to view the total content in your interested language
Der Pharma Chemica received 11575 citations as per Google Scholar report